Wall Street analysts predict that Hill-Rom Holdings, Inc. (NYSE:HRC) will announce $0.98 earnings per share for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Hill-Rom’s earnings. The highest EPS estimate is $0.99 and the lowest is $0.98. Hill-Rom posted earnings of $0.92 per share during the same quarter last year, which suggests a positive year-over-year growth rate of 6.5%. The firm is scheduled to issue its next earnings report on Friday, January 25th.
According to Zacks, analysts expect that Hill-Rom will report full year earnings of $5.13 per share for the current year, with EPS estimates ranging from $5.12 to $5.16. For the next financial year, analysts forecast that the company will post earnings of $5.73 per share, with EPS estimates ranging from $5.68 to $5.77. Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Hill-Rom.
Hill-Rom (NYSE:HRC) last announced its quarterly earnings results on Friday, November 2nd. The medical technology company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.51 by $0.12. Hill-Rom had a return on equity of 21.10% and a net margin of 8.86%. The firm had revenue of $759.20 million for the quarter, compared to analysts’ expectations of $750.90 million. During the same period in the prior year, the business posted $1.32 earnings per share. The business’s revenue was up 2.8% compared to the same quarter last year.
A number of analysts have weighed in on HRC shares. ValuEngine cut Hill-Rom from a “buy” rating to a “hold” rating in a research report on Thursday, October 4th. Barclays started coverage on Hill-Rom in a research report on Monday, October 15th. They issued an “equal weight” rating and a $95.00 price target on the stock. Raymond James upped their price target on Hill-Rom from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Monday, November 5th. Morgan Stanley upped their price target on Hill-Rom from $95.00 to $100.00 and gave the company an “equal weight” rating in a research report on Thursday, October 11th. Finally, Zacks Investment Research cut Hill-Rom from a “buy” rating to a “hold” rating in a research report on Wednesday, November 14th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $104.00.
NYSE:HRC traded down $3.28 during trading hours on Monday, reaching $92.76. The company had a trading volume of 4,657 shares, compared to its average volume of 429,445. Hill-Rom has a one year low of $78.16 and a one year high of $99.81. The stock has a market capitalization of $6.46 billion, a price-to-earnings ratio of 19.57, a price-to-earnings-growth ratio of 1.34 and a beta of 0.94. The company has a debt-to-equity ratio of 1.11, a current ratio of 1.74 and a quick ratio of 1.30.
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 31st. Stockholders of record on Friday, December 14th will be issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend is Thursday, December 13th. Hill-Rom’s payout ratio is presently 16.84%.
In other news, SVP Andreas G. Frank sold 7,454 shares of the stock in a transaction on Wednesday, November 28th. The stock was sold at an average price of $95.76, for a total transaction of $713,795.04. Following the sale, the senior vice president now owns 27,224 shares in the company, valued at $2,606,970.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.90% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of HRC. Hartford Investment Management Co. bought a new position in Hill-Rom in the second quarter valued at about $215,000. BNP Paribas Arbitrage SA boosted its holdings in Hill-Rom by 25.1% in the second quarter. BNP Paribas Arbitrage SA now owns 8,444 shares of the medical technology company’s stock valued at $737,000 after acquiring an additional 1,696 shares during the last quarter. Eqis Capital Management Inc. bought a new position in Hill-Rom in the second quarter valued at about $465,000. Aperio Group LLC boosted its holdings in Hill-Rom by 6.4% in the second quarter. Aperio Group LLC now owns 26,266 shares of the medical technology company’s stock valued at $2,294,000 after acquiring an additional 1,583 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new position in Hill-Rom in the second quarter valued at about $1,485,000. Institutional investors and hedge funds own 82.59% of the company’s stock.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Read More: Correction
Get a free copy of the Zacks research report on Hill-Rom (HRC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.